In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.
In the inaugural “Bladder Cancer Matters” podcast, host Rick Bangs interviews Dr. Ashish Kamat about the state of BCG in bladder cancer treatment. Dr. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. Dr. Kamat also serves on BCAN’s Scientific Advisory Board.
In this episode, Rick and Dr. Kamat discuss what BCG is, how it is used, why there is a BCG shortage and what some therapeutic alternatives are.
This episode is sponsored by FerGene, a new gene therapy company dedicated to creating and delivering innovative solutions for bladder cancer.
Click on this link to listen to the fascinating 30 minute conversation: https://bcan.org/what-up-with-bladder-cancer-and-bcg-with-dr-ashish-kamat/
Genetics May Predict Treatment Responses But Not Survival in Bladder Cancer
November 30th 2023Analysis of molecular subtypes of muscle-invasive bladder cancer can predict if a tumor is likely to respond to chemotherapy before surgery but is not associated with differences in survival.
Read More
Retired Teacher Turns to Former Student for Innovative Bladder Cancer Care
August 24th 2023“I treat all of my patients like my friends and family,” said Dr. Ravi Munver of Hackensack University Medical Center, who first met Peter Kahan as his honors physics teacher more than 35 years ago.
Listen